Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Comparison of posterior pole retinal and ganglion cell layer thickness asymmetry analysis in glaucoma suspects and healthy subjects

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Venue: Poster Village: Pod 2

First Author: : C.Altan TURKEY

Co Author(s): :    B. Arman   B. Basarir   M. Arici   B. Satana   N. Alagoz   I. Pasaoglu

Abstract Details


To evaluate the asymmetry of total retinal and ganglion cell layer (GCL) thickness between horizontal hemifields in the posterior pole in glaucoma suspects and healthy subjects using spectral domain optical coherence tomography (SD-OCT) as an early indicator of glaucomatous damage.


Beyoglu Eye Training and Research Hospital


Two hundred twenty six eyes of 113 subjects were included. Macular thickness (MT) and GCL thickness (GCLT) with posterior pole analysis mode was measured using SD-OCT. A hemifield was divided into five zones and compared with the reciprocal areas in the other hemifield. Differences in MTs (DMT1-5) and GCLTs (DGCLT1-5) between corresponding pairs of locations were calculated. Mean retinal thickness and GCLTs in each of the five zones was compared with the thickness of the corresponding zone in each eye. DMTs and DGCLTs of two eyes of each subject were compared within groups and between healthy eyes and glaucoma suspects.


A total of 164 glaucoma-suspect and 62 age-matched healthy eyes were included. Hemifield DMT 2, 4, 5 and DGCLT 2-5 were significantly differed between two groups (p˃0,05 for each). DGCLT 2 the only parameter that significantly differed in two eyes of each patient in glaucoma suspect group, however there were no significant differences between two eyes in terms of DMTs or DGCLTs in normals


Further studies are needed for the posterior pole asymmetry analysis with macular and ganglion cell layer thickness to be used as an assessment tool in the early diagnosis of glaucoma.

Financial Disclosure:


Back to previous